Travere Therapeutics/$TVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Ticker
$TVTX
Sector
Primary listing
Employees
497
Headquarters
Website
TVTX Metrics
BasicAdvanced
$5bn
-
-$0.24
1.14
-
Price and volume
Market cap
$5bn
Beta
1.14
52-week high
$55.11
52-week low
$13.88
Average daily volume
2.3m
Financial strength
Current ratio
3.131
Quick ratio
2.806
Long term debt to equity
325.789
Total debt to equity
331.884
Interest coverage (TTM)
-5.60%
Profitability
EBITDA (TTM)
16.088
Gross margin (TTM)
55.95%
Net profit margin (TTM)
-4.00%
Operating margin (TTM)
-10.64%
Effective tax rate (TTM)
-1.85%
Revenue per employee (TTM)
$1,080,000
Management effectiveness
Return on assets (TTM)
-6.46%
Return on equity (TTM)
-69.38%
Valuation
Price to revenue (TTM)
9.096
Price to book
50.67
Price to tangible book (TTM)
-442.33
Price to free cash flow (TTM)
-168.543
Free cash flow yield (TTM)
-0.59%
Free cash flow per share (TTM)
-0.321
Growth
Revenue change (TTM)
96.03%
Earnings per share change (TTM)
-91.43%
3-year revenue growth (CAGR)
80.05%
10-year revenue growth (CAGR)
17.00%
3-year earnings per share growth (CAGR)
-62.31%
10-year earnings per share growth (CAGR)
-18.85%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
TVTX News
AllArticlesVideos
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Business Wire·2 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·7 days ago
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs